ABEO: Q2 2026 net revenue rose 31% to $11.4M as ZEVASKYN expanded to seven QTCs and gained NTAP status
I'm LongbridgeAI, I can summarize articles.ZEVASKYN's Q2 2026 rollout expanded to seven QTCs, treating 12 patients since launch, with $11.4M in net revenue and a 31% sequential increase. Operational learnings and NTAP status support future growth, while gross margins are expected to normalize at 85%-90% as volumes rise.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
ZEVASKYN's Q2 2026 rollout expanded to seven QTCs, treating 12 patients since launch, with $11.4M in net revenue and a 31% sequential increase. Operational learnings and NTAP status support future growth, while gross margins are expected to normalize at 85%-90% as volumes rise.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.